|
|
|
|
| LEADER |
01257 am a22002053u 4500 |
| 001 |
164599 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Takeda, Andrea
|e author
|
| 700 |
1 |
0 |
|a Cooper, Keith
|e author
|
| 700 |
1 |
0 |
|a Bird, A.
|e author
|
| 700 |
1 |
0 |
|a Baxter, L.
|e author
|
| 700 |
1 |
0 |
|a Gospodarevskaya, Elena
|e author
|
| 700 |
1 |
0 |
|a Frampton, G.K.
|e author
|
| 700 |
1 |
0 |
|a Welch, Karen
|e author
|
| 700 |
1 |
0 |
|a Bryant, J.
|e author
|
| 245 |
0 |
0 |
|a Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation
|
| 260 |
|
|
|c 2010-09.
|
| 856 |
|
|
|z Get fulltext
|u https://eprints.soton.ac.uk/164599/1/mon1442.pdf
|
| 520 |
|
|
|a Study found that treatment with recombinant human growth hormone gave significantly greater benefits in stature for children with growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, chronic renal insufficency, short stature homeobox-containing gene deficiency, and those who were small for gestational age, than for untreated children. However, treatment was considered to be cost-effective at a willingness to pay threshold of £20,000-30,000 per quality-adjusted life-year gained only for children with GHD, although the analysis is subject to a range of important uncertainties
|
| 655 |
7 |
|
|a Article
|
